1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9817, H6Q-MC-JCBF, NCT00295815
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9815, H6Q-MC-S008, NCT00402116
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11183, H6Q-MC-S030, NCT00452413
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0018, NCT00052663
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8360, H6Q-MC-JCAO, NCT00088205
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8670, H6Q-MC-JCAQ, NCT00105092
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9098, H6Q-MC-JCAR, NCT00192114
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10463, H6Q-US-S002, NCT00267020
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10651, H6Q-US-S004, NCT00308750
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10287, H6Q-MC-S001, NCT00309140
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10517, H6Q-MC-S015, NCT00386087
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0170J, LILLY-H6Q-MC-S025, NCT00407758
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10708, H6Q-MC-S019, NCT00391118
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10737, H6Q-MC-S024, NCT00428714
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9819, H6Q-MC-S013, NCT00436280
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10538, H6Q-MC-S018, NCT00437268
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10536, H6Q-MC-S035, NCT00437294
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 4849, H6Q-MC-JCAI, NCT00042666
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9820, H6Q-MC-JCBT, NCT00530621
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11398, H6Q-MC-S034, NCT00533429
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11396, H6Q-MC-S038, NCT00536939
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10722, H6Q-MC-S021, NCT00538681
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11503, H6Q-MC-S057, NCT00542919
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0206061, LILLY-H6Q-MC-JCAH, NCI-G02-2132, NCT00052273
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-05-C-0136, NCT00112788
|
